Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

Partner | Cancer Centers | <b>Dana Farber</b>

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

In the trial, patients who were previously treated with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor and those who had not received platinum-containing chemotherapy or who are ineligible for cisplatin received enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4, explains Sonpavde.

Results from the trial showed a high objective response rate of 44%. Moreover, responses were reported irrespective of prior treatment with platinum-based chemotherapy or PD-1/PD-L1 inhibitors. Additionally, the median duration of response was 7.6 months.

Encouragingly, investigators also reported complete responses in 12% of patients and robust responses in patients with liver metastases. Going forward, Sonpavde hopes enfortumab vedotin will be approved for clinical use in this patient population.